CN107043787B - A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 - Google Patents
A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 Download PDFInfo
- Publication number
- CN107043787B CN107043787B CN201710355368.3A CN201710355368A CN107043787B CN 107043787 B CN107043787 B CN 107043787B CN 201710355368 A CN201710355368 A CN 201710355368A CN 107043787 B CN107043787 B CN 107043787B
- Authority
- CN
- China
- Prior art keywords
- marf1
- sgrna
- mouse
- cas9
- rite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091033409 CRISPR Proteins 0.000 title claims abstract description 47
- 101000957743 Homo sapiens Meiosis regulator and mRNA stability factor 1 Proteins 0.000 title claims abstract description 43
- 102100038620 Meiosis regulator and mRNA stability factor 1 Human genes 0.000 title claims abstract description 43
- 238000002703 mutagenesis Methods 0.000 title claims abstract description 23
- 231100000350 mutagenesis Toxicity 0.000 title claims abstract description 23
- 238000010172 mouse model Methods 0.000 title claims abstract description 18
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 238000010354 CRISPR gene editing Methods 0.000 title claims abstract 5
- 108020004414 DNA Proteins 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 25
- 238000012163 sequencing technique Methods 0.000 claims abstract description 21
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 12
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 11
- 238000013461 design Methods 0.000 claims abstract description 9
- 238000012546 transfer Methods 0.000 claims abstract description 7
- 230000002068 genetic effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000010367 cloning Methods 0.000 claims abstract description 4
- 208000007984 Female Infertility Diseases 0.000 claims abstract description 3
- 206010021928 Infertility female Diseases 0.000 claims abstract description 3
- 230000035772 mutation Effects 0.000 claims description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 239000003433 contraceptive agent Substances 0.000 claims description 3
- 230000002254 contraceptive effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000001850 reproductive effect Effects 0.000 abstract description 2
- 238000012790 confirmation Methods 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 60
- 235000013601 eggs Nutrition 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 230000029087 digestion Effects 0.000 description 15
- 239000003292 glue Substances 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000002322 Egg Proteins Human genes 0.000 description 8
- 108010000912 Egg Proteins Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000137 annealing Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 210000004681 ovum Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920000297 Rayon Polymers 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 7
- 239000012154 double-distilled water Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000000287 oocyte Anatomy 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000012372 quality testing Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000001177 vas deferen Anatomy 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150071661 SLC25A20 gene Proteins 0.000 description 2
- 108091028113 Trans-activating crRNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 101150102633 cact gene Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- NNKKTZOEKDFTBU-YBEGLDIGSA-N cinidon ethyl Chemical compound C1=C(Cl)C(/C=C(\Cl)C(=O)OCC)=CC(N2C(C3=C(CCCC3)C2=O)=O)=C1 NNKKTZOEKDFTBU-YBEGLDIGSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000001771 cumulus cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 210000000568 mesometrium Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 description 1
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010035533 Drosophila Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101100156889 Escherichia coli (strain K12) ygdG gene Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 101000835782 Homo sapiens Tudor domain-containing protein 5 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150012768 Marf1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100026393 Tudor domain-containing protein 5 Human genes 0.000 description 1
- 102000009322 Tudor domains Human genes 0.000 description 1
- 108050000178 Tudor domains Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000008182 oocyte development Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 101150009962 xni gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9, design the sgRNA sequences in efficient identification specific gene group PAM regions;And Donor DNA are designed in sgRNA sequence basis;By Donor DNA, sgRNA and Cas9 mRNA mixtures obtain founder mouse, and cloning and sequencing to embryonated egg procaryotic injection, embryo transfer, strain identified for genes, and confirmation finally gives genetic mouse catastrophic model.The present invention can be to improving human assistance reproductive technology, prevent and treat female infertility and female reproduction relevant disease, and the effective female contraception medicine of development of new all has important references value, and the healthy reproduction for promoting China or even global women is significant.
Description
Technical field
The present invention relates to gene code technical field, and in particular to uses CRISPR/Cas9 gene code technique constructions
The methods and applications of MARF1 rite-directed mutagenesis mouse models.
Background technology
MRAF1 proteins. Introductions
Soviet Union etc. is found that the Riken genes of the brand-new albumen of a coding past Unknown Function recently
(4921513D23Rik).The mouse for carrying the Gene unit point mutation and gene trap (gene trap) mutation shows together
The female sterile of sample and the normal table of male.Further study showed that the immediate cause for causing female sterile is female mice ovum mother
Cell can not recover meiosis and discharge immature egg mother cell.Accordingly, the unnamed gene is Marf1 by we
(meiosis arrest female 1).Clinically, MARF1 albumen also has great importance.On the basis that we test
On, once the crucial extron of maturation of ovum impaired patients gene was sequenced by Chen Zijiang etc., inquired into mankind's maturation of ovum obstacle
It is whether related to MARF1 genetic mutations.
MARF1 is a rna binding protein, and RRM (RNA recognition are typically of except possessing the albuminoid
Motif) outside, it possesses the domain (domain) of 1 similar ribalgilase (RNase) at N- ends, and 1 is possessed at C- ends newly
It is being found, be named as OST (oskar, tudor) or LOTUS (limkain, oskar and tudor domain
The and 7 of containing proteins 5) domain.OST/LOTUS domains exist in drosophila protein Oskar and the food in one's mouth
In newborn animal protein TDRD5 and 7 (and 7 of tudor domaincontaining proteins 5), and can by speculating
Those double-stranded RNAs formed after hybridizing with piRNA are particularly with reference to double-stranded RNA, they are then carried to reproduction cell
Inside such as nuage or germ granule privileged site.Oskar and TDRD5,7 determines (germ in drosophila reproduction cell respectively
Cell specification) and the meiosis of mouse male sex-cell and retrotransposon silence in play an important role
(Su.et.al.PNAS.2012).It is specifically shown in Fig. 1.
MARF1 albumen rite-directed mutagenesises
Protein structure databases NCBI-Structure (https://www.ncbi.nlm.nih.gov/ Structure/cdd/) conservative protein structure domain analogy is carried out, compare NYN and equally conservative XNI, 5 '-
EXONUCLEASE, TAQ DNA POLYMERASE, RIBONUCLEASE H, it is found that they possess 4 conservative Asp nucleases
Catalytic residue.It is corresponding in turn in the NYN of MARF1 albumen as D178, D215, D246, D272.In protein structure research, the third ammonia
Acid is the chiral amino acid that side chain is most short in amino acid.By the way that certain amino acid residue is sported into alanine, investigation can be passed through
Therefore whether the function of the mutain is mutated and loses or change, have crucial effect to the protein function so as to position
Amino acid residue.Alanine is replaced as, eliminates the active group on side chain, has changed small volume, the first without other functional groups into
Base, while the influence to protein structure is smaller.Therefore, the present invention have selected No. 272 sites of mutation, and aspartic acid (D) is prominent
It is changed into alanine (A).After MARF1 No. 272 aspartic acids (D) sport alanine (A), it can be used for specifically studying MARF1
NYN domains inactivation after influence to whole MARF1 albumen, further careful research MARF1 albumen lose NYN enzyme activity
Property after, to egg mother cell transcribe after mRNA steady-state adjustments influence.Particular sequence, which compares, sees Fig. 2.
CRISPR/Cas9 SYSTEM SUMMARYs
CRISPR (clustered, regularly interspaced, short palindromic repeats) is one
The immunologic mechanism of viral DNA or other exogenous DNAs of the kind from bacterial degradation invasion.In bacterium and archeobacteria, CRISPR systems
Altogether it is divided into 3 classes, wherein I class and III class need a variety of CRISPR GAP-associated protein GAPs (Cas albumen) to play a role jointly, and II class system
System only needs a kind of Cas albumen, and this can be extensively using the condition of providing convenience for it.At present, come from
Streptococcus pyogenes CRISPR/Cas9 systems are most widely used.Cas9 albumen (contains two nuclease knots
Structure domain, it is single-stranded that DNA two can be respectively cut.Cas9 is combined into compound with crRNA and tracrRNA first, then passes through
PAM sequences are combined and invade DNA, form RNA-DNA composite constructions, and then target DNA double-strand is cut, and make DNA double chain
Fracture.Because PAM sequential structures are simple (5 '-NGG-3 '), a large amount of target spots can be almost found in all genes, because
This is widely used.It is thin that CRISPR/Cas9 technologies have been successfully applied to plant, bacterium, yeast, fish and mammal
Born of the same parents, it is current most efficient genome editing technique.CrRNA and tracrRNA are transformed by genetic engineering means, will
It links together to obtain sgRNA (single guide RNA).RNA after fusion has the vigor similar with wild type rna,
But because structure is simplified, it is more convenient researcher and uses.It is specifically shown in Fig. 3.
The content of the invention
The technical problem of solution:The present invention provides a kind of based on CRISPR/Cas9 acquisition MARF1 rite-directed mutagenesis mouse models
Construction method and application, in the research of the horizontal gene M ARF1 albumen for carrying out egg mother cell predominant expression of animal.Especially may be used
To probe into when point mutation occurs, whether NYN domains can lose work, how to regulate and control Growth of Oocytes development to MARF1
During 3 key links-" acquisition of Meiotic resumption ability ", " mRNA post-transcriptional controls " and " retrotransposon sinks
It is silent " expansion more in-depth study.Present invention contemplates that MARF1 NYN domain action principles can be disclosed first, and will be deeply
Disclose the key mechanism that regulation and control Growth of Oocytes is reached maturity.This prevents and treats female acyesis to improving human assistance reproductive technology
Infertility and female reproduction relevant disease, and the effective female contraception medicine of development of new all have important references value, to promoting
The healthy reproduction for entering China or even global women is significant.
Technical scheme:A kind of construction method that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9, including
Following steps:1st step:The sgRNA sequences in the efficient identification specific gene group PAM regions of design, the sgRNA sequences such as SEQ
Shown in ID NO.1;And Donor DNA, the Donor DNA sequence dnas SEQ ID NO.2 institutes are designed in sgRNA sequence basis
Show;2nd step:By Donor DNA, sgRNA and Cas9 mRNA mixtures are to embryonated egg procaryotic injection, embryo transfer, strain gene
Identification, obtains founder mouse, and cloning and sequencing, confirms the genetic mouse mutation of MARF1-D272A point mutation finally given
Model.
What above-mentioned construction method obtained obtains MARF1 rite-directed mutagenesises mouse model in screening contraception based on CRISPR/Cas9
Application in medicine.
What above-mentioned construction method obtained obtains MARF1 rite-directed mutagenesises mouse model in screening preventing and treating based on CRISPR/Cas9
Application in female infertility or female genital disorders medicine.
The kit of MARF1 rite-directed mutagenesis mouse models is obtained, contains the sgRNA as shown in SEQ ID NO.1.
Donor DNA sequence dna of the mentioned reagent box shown in also containing SEQ ID NO.2.
Mentioned reagent box also contains Cas9 mRNA.
The specific building process of transgene mouse model is as follows:
1st, the structure of CRISPR-Cas system elements
In UCSC websites, MARF1 genomic dna sequence is downloaded.Intohttp://crispr.mit.edu/Website, it is defeated
Enter CDS sequences and search available sgRNA, 250bp is selected before and after MARF1-D272A point mutation position.Build px330-
SgRNA plasmids, and sgRNA in-vitro transcription templates are prepared, in-vitro transcription obtains sgRNA.Carry out Cas9 mRNA in-vitro transcriptions.
2nd, MARF1-sgRNA efficiency and Cas9 mRNA quality testings
Close up after making mouse superfecundation with public mouse, examine bolt, obtain more embryonated eggs.Prepare sgRNA and Cas9 mRNA
Mixture.By PCR, clone, sequencing, to determine the detection of sgRNA cleavage sites.
3rd, Donor DNA design, the procaryotic injection of MARF1 point mutation mouse and embryo transfer
Donor DNA are designed according to sgRNA cleavage sites, synthesize ssDNA.Prepare donor DNA, sgRNA and Cas9
MRNA mixtures, procaryotic injection, embryo transfer.
4th, the genotype identification of MARF1 point mutation mouse
Newborn small son is numbered, and clip part toe extraction genomic DNA.By PCR, clone, sequencing, to determine to be
It is no that there occurs the accurate restructuring of MARF1-D272A point mutation.It is final to establish the small of MARF1-D272A point mutation in mouse genome
Mouse model, the head of birth is on behalf of founder mouse;Each founder will be considered as an independent strain and be bred, right
Each founder strains are cut toe, the secondary PCR identifications for cutting tail first, and clone respectively and verification is sequenced.MARF1
272 asparagus fern amino acid mutations of albumen NYN domains are alanine, the amino acid sequence such as SEQ ID after the mutation
Shown in NO.1.
Beneficial effect:(1) structure provided by the invention that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9
Construction method, facilitate the multi-functional MARF1 of research in actual applications in terms of mouse propagation develops especially Oocyte Development
Mechanism of action, and the model can stablize passage.(2) mankind's ovum it is rare and by Medical Ethics limited can not easily as experiment
Object, " genetic modification mouse " are the important models for studying mankind's ovum.Research, production of the present invention for clinical female acyesis disease
Preceding diagnosis, the third generation " test-tube baby " PGD (preimplantation genetic diagnosis), that is, gene is examined before transplanting
The disconnected, progress of auxiliary procreation technology and the exploitation of contraceptive provide the effective research platform that can stablize heredity.
Brief description of the drawings
Fig. 1 .MARF1-NYN conservative domain site sequences compare figure.
Fig. 2 .MARF1-NYN conservative domain site sequences compare figure.
Fig. 3 .CRISPR-Cas9 SYSTEM SUMMARY figures.
Fig. 4 .MARF1-272-sgRNA-F1, MARF1-272-sgRNA-F2 are in genome shear efficiency figure.
Fig. 5 .MARF1-272 rite-directed mutagenesis Donor DNA sequence dnas, MARF1-272-sgRNA-F1, MARF1-272-
SgRNA-F2 is in the position of genome and corresponding PAM regions, and corresponding same sense mutation schematic diagram.
Fig. 6 .MARF1-D272A rite-directed mutagenesis mouse identification-PCR and StyI cleavage maps.
Fig. 7 .MARF1-D272A rite-directed mutagenesises mouse identification-sequencer map.
Identification-PCR and StyI cleavage maps after Fig. 8 .MARF1-D272A rite-directed mutagenesis cloned mouses.
Identification-sequencer map after Fig. 9 .MARF1-D272A rite-directed mutagenesis cloned mouses.
Figure 10 .MARF1 point mutation female mice egg mother cells and normal cell comparison diagram.
Figure 11 .MARF1 point mutation oocyte of mouse and normal cell Testing index comparison diagram, a left side for every group of data in figure
Side data post is normal cell, and right side data post is point mutation cell.
Embodiment
The experiment material needed in this experiment is specially:
Q5 High-fidelity 2XMaster Mix(NEB,M0492S)
2×Taq PCR Master Mix with loading dye(TIANGEN,KT201)
mMESSAGE mMACHINE T7 ULTRA kit(Ambion,AM1345)
MEGAshortscript TM T7ULTRA kit(Ambion,AM1354)
plasmid miniprep plus purification kit(genemark,Dp01-plus/Dp01-plus-
300)
Embodiment 1
A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9, with reference to
Specific embodiment, the present invention is expanded on further.
The structure of 1.1 CRISPR-Cas system elements
1.1.1 it is used for the design of the sgRNA sequences of gene knock-in
(1) enter UCSC websites, download MARF1 genomic dna sequence, with SnapGene software editing sequences.
(2) enter NCBI websites, according to gene information in sequence annotated exon, introne, promoter, coded sequence
(coding sequence, CDS) feature.
(3) enterhttp://crispr.mit.edu/Website, input CDS sequences are searched available sgRNA, surrounded
The front and rear selection 250bp in MARF1-D272A point mutation position.
(4) score value provided according to website selects sgRNA, and fraction is higher to represent that its effect of missing the target is lower, and sgRNA's is special
Property is better.Also to consider positions of the sgRNA on CDS simultaneously, use NCBI domain architecture
Retrieval instruments predict which important feature domain the albumen of gene C DS codings has, and ensure that sgRNA is located at domain as far as possible
Before.
1.1.2 px330-sgRNA plasmid constructions
(1) U6 promoters are carried on px330 plasmids, downstream close to 20 base-pairs (base pair, bp) sgRNA, its
It is the about 80bp general frame sequences of sgRNA afterwards.By original plasmid with after the single endonuclease digestions of Bbs I can be used for build new plasmid.
(2) oligodeoxynucleotide (DNA oligo, 5 ' → 3 ') is synthesized
sg-F:CACC-agtgatcttaggcaccggca
sg-R:AAAC-tgccggtgcctaagatcact
T7-sg-F:TAATACGACTCACTATAGGGagtgatcttaggcaccggca
T7-sg-R:AAAAGCACCGACTCGGTGCC
(3) oligo annealing (Anneal)
Mix, 37 DEG C of 30min in PCR instrument;95℃ 5min;0.1 DEG C/s is cooled to 25 DEG C
(4) fragment after annealing is connected to carrier
Mix, react at room temperature 3h, 6 μ L of conversion to E. coli competent, coated plate
(5) bacterium is chosen after 16h, adds 200 μ L 2 × YT culture mediums (Amp+) shake bacterium 2h, bacterium solution PCR
Mix, PCR reactions:95 DEG C of thermal startings, 58 DEG C of annealing, extend 15s, 35 × Cycles.
(6) 1% Ago-Gel is run, the positive bacterium of PCR identifications selects 3 to send sequencing, and sequencing primer is U6 promoter.
(7) the correct bacterium solution of sequencing result is small shakes upgrading grain for selection.
1.1.3 the preparation of sgRNA in-vitro transcriptions template
(1) DNA fragmentation (about 120bp) of high-fidelity enzyme PCR amplification codings sgRNA sequences, every sgRNA are identical with 2 pipes
System
Mix, PCR reactions:98 DEG C of thermal startings, 58 DEG C of annealing, extend 12s, 35 × Cycles.
(2) match somebody with somebody 1% Ago-Gel, run glue, cut bright band size 120bp or so blob of viscose, useGel
Extraction kits reclaim DNA.
A. blob of viscose is weighed, and 100mg is estimated as 100 μ L, adds the Buffer QG of 3 times of colloid products.
B.65 DEG C baking oven places 10min until blob of viscose melts.
C. the isopropanol of 1 times of colloid product is added, overturns and mixes.
D. mixture is transferred to adsorption column, 13000rpm centrifugation 1min, abandons filtrate.
E. 500 μ L Buffer QG, 13000rpm centrifugation 1min are added, abandon filtrate.
F. 750 μ L Buffer PE, 13000rpm centrifugation 1min are added, abandon filtrate.
G. repeat step f.
H. blank pipe centrifugation 2min.
I. adsorption column is transferred to clean 1.5mL imports centrifuge tube, uncap drying 5min in RNA super-clean benches.
J. the RNase-free ddH of 30 μ L, 65 DEG C of preheatings are added to adsorbed film center2O, it is stored at room temperature 5min.
K.13000rpm 2min elutions are centrifuged, 2 μ L is suctioned out and surveys concentration (DNA50).
1.1.4 sgRNA in-vitro transcription
(1) (complete) to use MEGAshortscript in RNA super-clean benches belowTMT7 transcript reagent boxes, with external
Responsive transcription system
Mix, 37 DEG C of reaction 4h.
(2) 0.5 μ L TURBO DNase are added, are mixed, 37 DEG C of reaction 15min.
(3) system is transferred to 0.6mL tubules, adds 125 μ L RNase-free ddH2O and 15 μ L Ammonium
Acetate Stop Solution, mix.
(4) isometric lower floor's phenol chloroform is added, overturns and mixes 10min, room temperature 12000rpm centrifugations 10min.
(5) upper strata aqueous phase is transferred to new pipe, adds isometric chloroform, overturned and mix 10min, room temperature 12000rpm centrifugations
10min。
(6) upper strata aqueous phase is transferred to new pipe, adds 2 times of volume absolute ethyl alcohols, mixed, -20 DEG C of placement 30min.
(7) 2% Ago-Gel is matched somebody with somebody, with RNase-free ddH2O matches somebody with somebody 75% ethanol, 4 DEG C of centrifuges of precooling.
(8) 4 DEG C of 12000rpm centrifuge 15min.
(9) supernatant is abandoned, rinses a precipitation with the ethanol of 500 μ L 75%, 4 DEG C of 12000rpm centrifuge 5min.
(10) most supernatant is abandoned, drying to the edge of precipitation of being uncapped in RNA platforms tends to be transparent.
(11) precipitation size is regarded, adds 50~80 μ L RNase-free ddH2O dissolves, and places 2~3min on ice.
(12) mix, stay 3 μ L, remaining 6 μ L/ pipes packing, freeze in -80 DEG C of refrigerators.
(13) concentration (ssDNA33) is surveyed, records 260/280 (2.0~2.2 be normal).
(14) take 1 μ L to run 2% Ago-Gel, 130V 8min, check whether band brightness is consistent with concentration, and band is big
It is small whether in 100bp or so.
1.1.5 Cas9 mRNA in-vitro transcriptions
(1) single endonuclease digestion pSpCas9 (BB) (pX330;Addgene plasmid ID:42230) plasmid, as in-vitro transcription
Template
Mix, 37 DEG C of reactions are overnight.
(2) match somebody with somebody 1% Ago-Gel, run glue, blob of viscose where cutting linearisation DNA, useGel
Extraction kits reclaim.
(3) mMESSAGE is usedT7 transcript reagent box in-vitro transcription Cas9 mRNA.
(1. being completed below in RNA super-clean benches) matches somebody with somebody external responsive transcription system
Mix, 37 DEG C of reaction 2h.
2. adding 1 μ L TURBO DNase, mix, 37 DEG C of reaction 15min.
3. with addition of the reaction system of polyA tails
Mix, suction out 2.5 μ L and preserve on ice.
4. adding 4 μ L E-PAP Mix, mix, 37 DEG C of reaction 30min, be put on ice.
5. adding 10 μ L Ammonium Acetate Stop Solution, mix.
6. phenol chloroform method carries out RNA purifying, step is same as 1.1.4 (4)~(10).
7. depending on precipitating size, Nuclease-free water dissolvings are added, place 2~3min on ice.
8. mixing, 1.5 μ L are taken to survey concentration (RNA40), 260/280 2.0 or so is normal, and remaining mRNA is temporarily put in ice
On.
9. mRNA is diluted into about 1 μ g/ μ L according to concentration is measured, takes 1 μ L and add 2.5 μ L before polyA tails to run 2% fine jade
Sepharose, should have obvious bright band under normal circumstances plus before polyA tails, add the band after polyA tails should it is bigger (may slightly mould
Paste, does not influence to use).
10. if concentration, the cementing fruit of race are normal, often pipe dispenses 1 μ g, freezes rapidly in -80 DEG C of refrigerators, obtains Cas9
mRNA。
1.2 MARF1-sgRNA efficiency and Cas9 mRNA quality testings
In once testing, it can determine that efficient sgRNA detects Cas9 mRNA quality with 1, it is also possible to high quality
Cas9 mRNA detect 1 sgRNA efficiency.
1.2.1 the acquisition of mouse fertilized egg
Embryo for Efficiency testing is typically derived from BDF1 Strains of Mouse, and it is inbred strais C57BL/6J and DBA/2 mouse
The first generation filial generation that post-coitum is cultivated, sexal maturity in 6~8 weeks.The mouse used is raised in no-special pathogen
(specific-pathogen-free,SPF)。
(1) 0d, 13:00, capture the week old BDF1 female mices of 8 weeks or so, intraperitoneal injection 50U/mL (about 60 μ L) pregnant horse blood
Clear promoting sexual gland hormone (pregnant mare ' s serum gonadotropin, PMSG), imitates endogenous follicle-stimulating hormone
The promotion maturation of ovum effect of (follicle-stimulating hormone, FSH).
(2) 2d, 13:00, PMSG BDF1 female mices, intraperitoneal injection 50U/ml (about 70 μ L) human chorionic were injected in crawl
Promoting sexual gland hormone (human chorionic gonadotropin, hCG), imitate luteotropin (luteinizing
Hormone, LH) induced ovulation effect.And every female mice is individually mated with 1 BDF1 public affairs mouse and mated.
(3) G1 Embryo Culture drops are done:35mm Petri culture dishes bottom, about 20 μ L/ drops, proper alignment, is finally used
Mineral oil seal liquid level, 37 DEG C, 5%CO2Balanced overnight in incubator.
(4) 3d, 8:00, check female mice whether there is vaginal plug (the secretion vestige that public mouse post-coitum leaves), if any then taking out
Mouse room.
(5) CZB Embryo Culture drops are done, 37 DEG C, 5%CO215min is at least balanced in incubator.
(6) cervical dislocation puts to death female mice:Mouse is placed on the brandreth of mouse cage, its fore paw is caught steel wire above
Bar, its neck (after skull) is tightly pushed down, while level stretches afterbody backward, makes its disconnected neck.
(7) mouse back of execution is put in Enamel jar upward, sprays mouse back with 75% alcohol immediately, subtract as far as possible
The pollution of few mouse hair.
(8) mouse back skin is pinched, an osculum is cut off in Zhong Xiaqu with surgery scissors, firmly catches the skin cut off
Skin, skin of back is set to open completely to head and afterbody stretching, hair also leaves interior tissue completely.
(9) open notacoria with ophthalmic tweezers and sharp scissors, white adipose tissue picked up with tweezers, lightly uterus,
Fallopian tubal, ovary and fat pad integrally pull out body cavity, and the uterus below ovary is clamped with tweezers, with scissors close to fallopian tubal
A hole is pierced on mesometrium, cuts off mesometrium, then ovary is separated with fallopian tubal with scissors (ensures the complete of fallopian tubal
Property), finally cut close to the uterus of fallopian tubal, fallopian tubal is put into HCZB manipulation in vitro liquid.
(10) ampulla that fallopian tubal expands is punctured with the needle point of syringe under anatomical lens, obtains cumulus cell parcel
Embryonated egg group.
(11) all agglomerates are collected, in 0.1% hyaluronidase after 37 DEG C of 3~5min of digestion, embryonated egg is thin with ovarian cumulus
Born of the same parents separate.
(12) calcination glass capillary draws pin and broken needle, about 150~200 μm of internal diameter, assembling on the flame of alcolhol burner
Mouth suction pipe.Ovum is moved with mouth suction pipe, the embryonated egg separated washes 6 times in HCZB drops, washes away the cumulus cell of residual and transparent
Matter acid enzyme.
(13) embryonated egg is moved into CZB drops and washes 3 times, 37 DEG C, 5%CO2Recover in incubator.
1.2.2 sgRNA and Cas9 mRNA mixtures are prepared
Mixture is prepared in RNA platforms.The Cas9 mRNA and 50ng/ μ L that mixture for detection efficiency is 100ng/ μ L
SgRNA.General injection need to prepare 5 μ L mixtures
Cas9 mRNA 500ng
sgRNA 250ng
ddH2O is mended to 5 μ L
4 DEG C of 10000rpm centrifuge 10min, and procaryotic injection is into about 20 pieces of embryonated eggs.
1.2.3 the detection of sgRNA cleavage sites
A. the cracking of embryo
(1) embryonated egg is cultivated 3 days in G1 nutrient solutions, is developed to after blastaea and embryo is moved into 5 μ L G1 cracking with mouth suction pipe
In liquid.
(2) 95 DEG C of 20min cracking embryo's released dnas in PCR instrument.
(3) 5 μ L G2 solution are added, mixes, pcr template can be used as.
B.PCR is expanded
(1) with the high primer of NCBI Primer-BLAST tool designs specificity, PCR primer is mouse gene group DNA
The upper 500bp comprising sgRNA sites or so fragment, sgRNA sites should try one's best in fragment center.
(2) primer specificity is tested with common mouse gene group DNA, thermograde PCR is to obtain the optimal annealing of primer
Temperature.
(3) first round PCR reacts
Mix, PCR reactions:94 DEG C of thermal startings, extend 36s, 30 × Cycles.
(4) second wheel PCR reactions, each sample match somebody with somebody 2 pipe same systems;Simultaneously with 2 pipes with wild type (wild type,
WT) mouse gene group DNA is the system of template
Mix, PCR reactions:95 DEG C of thermal startings, extend 36s, 35 × Cycles.
(5) match somebody with somebody 1% Ago-Gel, run glue, cut the correct blob of viscose of band, reclaimed using DNA purifying QIAquick Gel Extraction Kits
DNA。
1. blob of viscose is weighed, 100mg is estimated as 100 μ L, adds the Buffer PC of equimultiple colloid product.
2. 65 DEG C of baking ovens place about 10min until blob of viscose melts.
3. equilibrium adsorption post:500 μ L Buffer BL, 13000rpm centrifugation 1min are added, abandon filtrate.
4. sol solutionses are added in adsorption column, 5min is stored at room temperature, 13000rpm centrifugation 1min, abandons filtrate.
5. adding 600 μ L Buffer PW, 13000rpm centrifugation 1min, filtrate is abandoned.
6. repeat step is 5..
7. blank pipe centrifuges 2min.
8. adsorption column is transferred into clean 1.5mL centrifuge tubes, uncap drying 5min in super-clean bench.
9. adding the Buffer EB of 30 μ L, 65 DEG C of preheatings to adsorbed film center, 5min is stored at room temperature.
10. 13000rpm centrifugation 2min elutions, suction out 1.7 μ L and survey concentration (DNA50).
C. glue returns the T7 digestions experiment of product
(1) annealing reaction system is matched somebody with somebody
250~300ng of glue reclaim product DNA
NEB Buffer 2 1.5μL
ddH2O is mended to 14.5 μ L
Mix, denaturation, annealing reaction in PCR instrument:95 DEG C of 5min, 0.1 DEG C/s slow coolings are to 25 DEG C, 25 DEG C of 10min.
(2) 2% Ago-Gel is matched somebody with somebody.
(3) 0.5 μ L T7 restriction endonucleases I are added to DNA annealing systems, mixed, 37 DEG C of 15~17min of reaction in PCR instrument.
(4) 10 × Loading Buffer are rapidly added, are mixed, 135V voltages run glue 30min, result are checked, if removed
There is obvious band less than normal outside about 500bp master tapes, and WT is without then illustrating the piece that mutation is contained in virgin rubber recovery product
Section, corresponding sgRNA may have cutting to cause to be mutated.
D. sequencing vector is connected
(1) positive glue is tested into T7 digestions and returns fragment connection sequencing vector, there are two kinds of commercial vectors can use.
a.pLB vector
1. match somebody with somebody end-filling reaction system
Mix, 20 DEG C of 5min, 70 DEG C of 5min in PCR instrument, it is of short duration on ice.
2. match somebody with somebody coupled reaction system
The μ L of filling-in product 4
pLB vector 0.5μL
T4Ligase 0.5μL
Mix, room temperature places 10min, all to E. coli competent, coated plate.
b.Zero Cloning
With coupled reaction system
Glue reclaim product 25ng
T5 Zero Cloning Vector 1μL
ddH2O is mended to 4 μ L
Mix, room temperature places 15min, is totally converted to E. coli competent, coated plate.
(2) bacterium is chosen after 16h, adds 200 μ L 2 × YT culture mediums (Amp+) shake bacterium 2h, bacterium solution PCR
Mix, PCR reactions:95 DEG C of thermal startings, extend 36s, 35 × Cycles.
(3) 1% Ago-Gel is run, the positive bacterium of PCR identifications selects 8 to send sequencing, and sequencing primer is T7 promoter.
Result is checked, the result comprising insertion/deletion (insertion/deletion, indel) mutation accounts for the proportional representation of sum
Corresponding sgRNA efficiency.
(4) for the sample of T7 digestion negatives, glue is directly returned into fragment and send sequencing, checks the peak figure of sequencing, if
All it is single peak before sgRNA cleavage sites, and starts to ending have set peak in sgRNA vicinity, then the glue returns product
The fragment (false negative is tested in T7 digestions) of mutation is may included, is attached the presence that sequencing vector confirms mutation.
1.3 Donor DNA design and the procaryotic injection of MARF1 point mutation mouse
1.3.1 Donor DNA design
It is by sgRNA1 PAM regions 5 ' between extreme direction 3-4bp centered on cutting position, respectively to 5 ' extreme direction 65bp
Left side homology arm, 3 ' extreme direction 65bp is right side homology arm, orders single-stranded ssDNA (raw work, Shanghai China).The single-stranded ssDNA
Purity have to using HPLC purify.
MARF1-272-sgRNA-1, MARF1-272-sgRNA-2 cutting efficiency, which compare, sees Fig. 4.
MARF1-272donor DNA design collection of illustrative plates is shown in Fig. 5.
1.3.2 donor DNA, sgRNA and Cas9 mRNA mixtures are prepared
Mixture is prepared in RNA platforms.The Cas9 mRNA and 50ng/ μ L that mixture for detection efficiency is 100ng/ μ L
SgRNA, 100ng/ μ L donor DNA.General injection need to prepare 5 μ L mixtures
4 DEG C of 10000rpm centrifuge 10min, and kytoplasm is injected in about embryonated egg.
1.3.3 procaryotic injection
The acquisition of embryonated egg, and procaryotic injection have described, and ibid, see sgRNA efficiency and Cas9 mRNA quality testings.
1.3.4 embryo transfer
A, the preparation of public mouse is ligatured
(1) 6-8 week old public affairs mouse are anaesthetized by 100ml/kg dosage after weighing, mouse is fixed in back of the body position, and 75% ethanol, which applies, to be put on the skin
Sterile surgical cutting part, to prevent hair contamination of incision.
(2) row cuts off lower abdomen skin about 1.3cm in front of the genitals, work about 1cm otch, with soaking 75% second
The gauze of alcohol is wiped over cutting part to clear up hair.
(3) peritonaeum is cut, carries out bladder positioning.There is a pipeline traveling per side is all visible, left side is gently clamped with tweezers
Pipeline, lifting part makes surgical field of view high-visible, determines that it is vas deferens.
(4) vas deferens is pinched into tweezers it is U-shaped, it is another that tweezers are heated on alcolhol burner, scalded between 2 ligation points disconnected defeated
Spermaduct, the vas deferens of ligation is put into and carries out opposite side ligation again in vivo.
(5) after the operation of both sides, with art mouth inside and outside the suture of 0-5 sutures.Mouse is put on 37 DEG C of thermostatic platforms directly
To revival.Post operation Mouse feeder determines whether operation succeeds after 2 weeks.
(6) experimental raising:1-2 dams and vasectomy mouse are mated into raising, secondary morning carries out vaginal plug inspection.
The dams for having vaginal plug can make smear of bolt, and sperm has been seen whether under microscope.Also it can cultivate to next day and take fallopian tubal inspection
Whether two cell stages are had.If sperm or there are two cell stages then the ligation of public mouse is unsuccessful.
B, the preparation of acceptor mouse
(1) while the ICR or CD-1 of heat are selected and the public mouse of ligation mates.
(2) m seq checks whether donor mouse and acceptor mouse see bolt, is used for embryo transfer on the day of seeing bolt or after 2.5.
C, common oviduct transplantation
(1) operating theater instruments, suture of sterilization etc. are got out.
(2) implement the anesthesia of 1.25% avertin solution to mouse by 200ml/kg dosage after weighing, cut off mouse back
Hair, it is about concordant with last 1 rib to locate in backbone side 1cm after 75% alcohol disinfecting, skin is cut off, with tweezers along notch bluntness
Integumentary musculature is separated, ovary, fallopian tubal and uterus are gently pulled out with tweezers, clamps partial fat, is placed on the skin of mouse behind.
(3) embryonated egg survived after sucking 20 pieces of injections with transplanting pin, suction order are:M16 nutrient solution & Kong Qis &M16 is trained
Nutrient solution & air & embryonated eggs, in the case where ensureing that embryo is fully entrained, the soakage of nutrient solution is reduced as far as possible.
(4) mouse is placed under anatomical lens, fat pad is pinched with small size haemostatic clamp, the film of ovary will be wrapped up with ophthalmology tweezers
An osculum is torn, exposes fimbriae tubae portion, insertion moves ovum pin, embryonated egg is blown into fallopian tubal, ampulla of uterine tube has bright
Aobvious bubble shows to transplant successfully.
(5) fat pad, ovary, uterus and fallopian tubal are sent back to abdominal cavity, peritoneal suture and skin incision in the lump with blunt tweezers,
The acceptor mouse transplanted is placed to be transplanted in barrier environment after 10min recovers on warm platform and raised.
(6) mouse after transplanting makes marks, and indicates transplant time, family name, embryo's quantity.Date of birth is indicated after farrowing
Phase and birth quantity, the survival condition of the young baby of observation birth daily.
1.4.MARF1 the genotype identification of point mutation mouse
After RNA injects embryonated egg and is transplanted in false pregnancy dams fallopian tubal, general 19~20 days fertility mouse.Mouse is born
After 6 days, separated between its toe, toe can be cut and make numbering mark, cut the extracting that tail point fritter tissues are used for genomic DNA.
1.4.1 the phenol chloroform of genomic DNA
(1) clip tissue is put into centrifuge tube, adds the rat-tail lysate that 300 μ L contain Proteinase K, 65 DEG C of cracking are overnight.
(2) 300 μ L phenol chloroforms are added, overturns and mixes 10min, room temperature 12000rpm centrifugations 10min.
(3) carefully draw supernatant and move to new pipe, add the absolute ethyl alcohol of two volumes, it is visible cotton-shaped heavy to overturn mixing
Form sediment, 4 DEG C of 12000rpm centrifuge 5min.
(4) supernatant is abandoned, adds the ethanol of 500 μ L 70% rinsing precipitation, 4 DEG C of 12000rpm centrifuge 5min.
(5) most supernatant is abandoned, super-clean bench dries up 5min to bottom precipitation bleach, depending on precipitating size, 65 DEG C of preheatings of addition
ddH2O。
(6) room temperature, which places 5min, makes DNA fully dissolve.
(7) overturn and mix, suction out 2 μ L and survey concentration (DNA50).
1.4.2 the PCR amplifications comprising prediction mutational site fragment
(1) primer used is identical with during sgRNA Efficiency testings, and each DNA sample regards primer efficiency and prepares 2~3 pipes
Reaction system
(2) glue reclaim, the same 3.2.3B. of step (5).
1.4.3 the direct StyI digestions experiment of Genomic PCR products and sequencing confirm
(1) the direct StyI digestions experiment of PCR primer:
(2) 37 degree, water-bath, digestion 3h, electrophoresis.
(3) PCR primer direct Sequencing.
Due to the change of rite-directed mutagenesis, in the event of accurate restructuring, it will one restriction enzyme site StyI of increase.Wild type
Mouse can not then be cut open.The mouse that the present invention is born, #1 can be by StyI digestions, but #2, #3, #4, #5 cannot
It is digested.See Fig. 6 in detail.Accurate restructuring occurs in order to further confirm that, sequencing is it can be found that the point mutation position meeting of restructuring
Appearance one is significant bimodal.And the mouse of wild type is not in then bimodal.The mouse that the present invention is born, #1 have bimodal, but #
2, #3, #4, #5 be not bimodal.See Fig. 7 in detail.
1.4.4 StyI digestions experiment and sequencing confirm after PCR primer clone
After PCR primer is by QIANGEN kit glue reclaims, connected with PLB vector kits, clone, choose bacterium,
Monoclonal, bacterium solution PCR is, filters out positive bacteria.On the one hand, PCR primer is directly used into StyI digestions, electrophoresis, monoclonal bacterial strain
L5, L9 can be by StyI digestions, but monoclonal bacterial strain L1, L2, L3, L4, L6, L7, L8 cannot be shown in Fig. 8 by StyI digestions.
On the other hand, monoclonal positive bacteria is sent into company's sequencing, sequencing result is shown in Fig. 9.
The application infertile as genetic model research female is stablized of 1.5 MARF1 point mutation mouse
1.5.1 MARF1 point mutation female mice is infertile, and egg mother cell is unable to normal development
As shown in Figure 10.MARF1 point mutation oocyte of mouse is arrested in germ-vesicle (GV) period, it is impossible to recovers subtrahend
Division, it is impossible to normal mature.It is infertile to further result in female.
1.5.2 MARF1 point mutation oocyte of mouse series Testing index RNA significantly rises
As shown in figure 11.Substantial amounts of Testing index RNA significantly rises in MARF1 point mutation oocyte of mouse, and normal
Substantial amounts of Testing index RNA maintains reduced levels in egg mother cell.These can be pre-natal diagnosis, the third generation " test-tube baby "
PGD (preimplantation genetic diagnosis), that is, transplant before gene diagnosis, the progress of auxiliary procreation technology with
And the exploitation of contraceptive provides the effective research platform that can stablize heredity.
SEQUENCE LISTING
<110>Nanjing Medical University
<120>A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9
<130>
<160> 10
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213>Artificial sequence
<400> 1
agtgatctta ggcaccggca 20
<210> 2
<211> 130
<212> DNA
<213>Artificial sequence
<400> 2
atgcttgtat ttttcctttc agctgctgtc aattttgcct tggaactcag tgatcttagg 60
catcggcacg gtttccacat cattttggta cataaaaacc aggcctctga agccttgtta 120
catcatgcta 130
<210> 3
<211> 24
<212> DNA
<213>Artificial sequence
<400> 3
caccagtgat cttaggcacc ggca 24
<210> 4
<211> 24
<212> DNA
<213>Artificial sequence
<400> 4
aaactgccgg tgcctaagat cact 24
<210> 5
<211> 40
<212> DNA
<213>Artificial sequence
<400> 5
taatacgact cactataggg agtgatctta ggcaccggca 40
<210> 6
<211> 20
<212> DNA
<213>Artificial sequence
<400> 6
aaaagcaccg actcggtgcc 20
<210> 7
<211> 24
<212> DNA
<213>Artificial sequence
<400> 7
caccagtgat cttaggcacc ggca 24
<210> 8
<211> 24
<212> DNA
<213>Artificial sequence
<400> 8
aaactgccgg tgcctaagat cact 24
<210> 9
<211> 20
<212> DNA
<213>Artificial sequence
<400> 9
tgtgattgcc ctgtcatgct 20
<210> 10
<211> 20
<212> DNA
<213>Artificial sequence
<400> 10
agagaggctc aaaaggctgc 20
Claims (5)
1. a kind of construction method that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9, its feature include following step
Suddenly:
1st step:The sgRNA sequences in the efficient identification specific gene group PAM regions of design, the sgRNA sequences such as SEQ ID
Shown in NO.1;And Donor DNA are designed in sgRNA sequence basis, shown in the Donor DNA sequence dnas SEQ ID NO.2;
2nd step:By Donor DNA, sgRNA and Cas9 mRNA mixtures are to embryonated egg procaryotic injection, embryo transfer, strain base
Because of identification, founder mouse, and cloning and sequencing are obtained, the genetic mouse for the MARF1-D272A point mutation for confirming to finally give is dashed forward
Varying model.
Exist 2. what construction method described in claim 1 obtained obtains MARF1 rite-directed mutagenesis mouse models based on CRISPR/Cas9
Screen the application in contraceptive.
Exist 3. what construction method described in claim 1 obtained obtains MARF1 rite-directed mutagenesis mouse models based on CRISPR/Cas9
Application in screening preventing and treating female infertility medicine.
4. obtain the kit of MARF1 rite-directed mutagenesis mouse models, it is characterised in that contain the Donor shown in SEQ ID NO.2
DNA sequence dna and the sgRNA as shown in SEQ ID NO.1.
5. kit according to claim 4, it is characterised in that also containing Cas9 mRNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710355368.3A CN107043787B (en) | 2017-05-19 | 2017-05-19 | A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710355368.3A CN107043787B (en) | 2017-05-19 | 2017-05-19 | A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107043787A CN107043787A (en) | 2017-08-15 |
CN107043787B true CN107043787B (en) | 2017-12-26 |
Family
ID=59547089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710355368.3A Expired - Fee Related CN107043787B (en) | 2017-05-19 | 2017-05-19 | A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107043787B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109266680B (en) * | 2018-10-17 | 2020-09-25 | 江苏集萃药康生物科技有限公司 | Method for preparing CKO/KI animal model by using Cas9 technology |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
GB2568182A (en) | 2016-08-03 | 2019-05-08 | Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
KR102622411B1 (en) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | AAV delivery of nucleobase editor |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
EP3601562A1 (en) | 2017-03-23 | 2020-02-05 | President and Fellows of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
EP3676376A2 (en) | 2017-08-30 | 2020-07-08 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
CN107475300B (en) * | 2017-09-18 | 2020-04-21 | 上海市同济医院 | Construction method and application of Ifit3-eKO1 gene knockout mouse animal model |
KR20200121782A (en) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | Uses of adenosine base editor |
CN108410876B (en) * | 2018-03-26 | 2021-08-31 | 浙江中医药大学 | Method for constructing spontaneous anemia mouse model with leukocytosis and thrombocytosis |
BR112021018606A2 (en) | 2019-03-19 | 2021-11-23 | Harvard College | Methods and compositions for editing nucleotide sequences |
DE112021002672T5 (en) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9970001B2 (en) * | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
WO2016176191A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Dual aav vector system for crispr/cas9 mediated correction of human disease |
CN105296518A (en) * | 2015-12-01 | 2016-02-03 | 中国农业大学 | Homologous arm vector construction method used for CRISPR/Cas 9 technology |
-
2017
- 2017-05-19 CN CN201710355368.3A patent/CN107043787B/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109266680B (en) * | 2018-10-17 | 2020-09-25 | 江苏集萃药康生物科技有限公司 | Method for preparing CKO/KI animal model by using Cas9 technology |
Also Published As
Publication number | Publication date |
---|---|
CN107043787A (en) | 2017-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107043787B (en) | A kind of construction method and application that MARF1 rite-directed mutagenesis mouse models are obtained based on CRISPR/Cas9 | |
CN108660161B (en) | Method for preparing chimeric gene-free knockout animal based on CRISPR/Cas9 technology | |
CN109777837A (en) | A method of the systemic knock-out mice model of lethal gene is constructed using CRISPR/Cas9 system | |
CN106119284A (en) | A kind of product for building immunodeficient animals model and application thereof | |
CN107937345A (en) | A kind of fibroblastic method of pig for preparing while knocking out CD163 genes and CD13 genes | |
CN113957093B (en) | System for site-directed modification of pAPN gene and application thereof | |
CN113604504A (en) | Composition for site-directed modification of pAPN gene 16 exon and application thereof | |
JP2023116719A (en) | Disease model pig exhibiting stable phenotype, and production method thereof | |
Sarvari et al. | A technique for facile and precise transfer of mouse embryos | |
Nicholls | Let's make a mommoth | |
CN117487855A (en) | Methods for improving swine health by targeted inactivation of CD163 | |
CN109811009A (en) | A method of lethal gene function is analyzed using CRISPR/Cas9 system building knock-out mice model | |
JPH04504352A (en) | Method for introducing exogenous DNA into animal somatic cells and reproductive cells | |
CN113549637B (en) | SNP locus of mouse PHEX gene and application thereof | |
Ghassemi et al. | Pipeline for the generation of gene knockout mice using dual sgRNA CRISPR/Cas9-mediated gene editing | |
CN113549638A (en) | Method for constructing mouse model of X-linked rickets with low blood phosphorus | |
CN110129320B (en) | Method for obtaining gene editing sheep and sgRNA and Oligo DNA special for same | |
CN107937439B (en) | Application of gene and construction method of animal model | |
CN109777828A (en) | A kind of genetic modification animal model preparation method based on IVF Yu CRISPR/Cas9 gene editing technology | |
Huang et al. | Generation of cynomolgus monkey fetuses with intracytoplasmic sperm injection based on the MII-stage oocytes acquired by personalized superovulation protocol | |
JP2966016B2 (en) | Transgenic rat and method for producing the same | |
CN110438155A (en) | Modify composition, application, cell and the preparation method of gene editing pig of the 561st amino acids of CD163 gene | |
CN113615638B (en) | Construction method and application of precocious sexual animal model | |
CN114875074B (en) | Method for improving polyclonal rabbit antibody production | |
CN111808859B (en) | gRNA of WAS gene and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171226 Termination date: 20210519 |
|
CF01 | Termination of patent right due to non-payment of annual fee |